Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia

Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a peak incidence at 67 years. Patients older than 60 years have an unfavorable prognosis due to resistance to conventional chemotherapy. Volasertib (BI 6727) is a cell-cycle re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopalakrishnan, Bhavani, Cheney, Carolyn, Mani, Rajeswaran, Mo, Xiaokui, Bucci, Donna, Walker, Alison, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Rueter, Bjoern, Waizenegger, Irene C., Heider, Karl-Heinz, Blum, William, Vasu, Sumithira, Muthusamy, Natarajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839395/
https://www.ncbi.nlm.nih.gov/pubmed/29515764
http://dx.doi.org/10.18632/oncotarget.23880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839395/
https://www.ncbi.nlm.nih.gov/pubmed/29515764
http://dx.doi.org/10.18632/oncotarget.23880

Ejemplares similares